FDA: Lilly Drug Did Not Lead To Suicide
The Food and Drug Administration has concluded that Eli Lilly and Co.’s newly approved antidepressant Cymbalta did not trigger the suicide of a woman from Bensalem, Pa., who was taking part in a clinical trial. An FDA investigation found that Cymbalta could not be linked to the death of Traci Johnson, who hanged herself with a scarf in Lilly’s Indianapolis drug-testing clinic.
Dr. John Grohol is the CEO and founder of Psych Central. He is an author, researcher and expert in mental health online, and has been writing about online behavior, mental health and psychology issues -- as well as the intersection of technology and human behavior -- since 1992. Dr. Grohol sits on the editorial board of the journal Cyberpsychology, Behavior and Social Networking and is a founding board member and treasurer of the Society for Participatory Medicine.Like this author?
Catch up on other posts by John M. Grohol, PsyD (or subscribe to their feed).
Comments
This post currently has no comments. You can read the comments or leave your own thoughts on our new comments page.
Trackbacks
Last reviewed: By John M. Grohol, Psy.D. on 18 Aug 2004
Published on PsychCentral.com. All rights reserved.
APA Reference
Grohol, J. (2004). FDA: Lilly Drug Did Not Lead To Suicide. Psych Central. Retrieved on February 14, 2012, from http://psychcentral.com/blog/archives/2004/08/17/fda-lilly-drug-did-not-lead-to-suicide/
Grohol, J. (2004). FDA: Lilly Drug Did Not Lead To Suicide. Psych Central. Retrieved on February 14, 2012, from http://psychcentral.com/blog/archives/2004/08/17/fda-lilly-drug-did-not-lead-to-suicide/
